Australian Clinical Labs Ltd (AU:ACL) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Limited (ASX:ACL) announced the successful passage of all resolutions at its 2024 Annual General Meeting, including the adoption of the remuneration report and the re-election of director Michael Alscher. The renewal of the shareholder-approved LTVR plan also received overwhelming support. Investors can find more details and a recording of the meeting on the company’s website.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.